Comparison of solifenacin and fesoterodine in treatment of overactive bladder

References

1. ↵
   1. Haylen BT,
   2. de Ridder D,
   3. Freeman RM,
   4. Swift SE,
   5. Berghmans B,
   6. Lee J,
   7. et al.

   (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29:4–20.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Cheung WW,
   2. Khan NH,
   3. Choi KK,
   4. Bluth MH,
   5. Vincent MT

   (2009) Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 10:8.

   OpenUrlPubMed
3. ↵
   1. Harnett MD,
   2. Shipley J,
   3. MacLean L,
   4. Schwiderski U,
   5. Sandage BW Jr.

   (2013) Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects. Clin Drug Investig 33:133–141.

   OpenUrl
4. ↵
   1. Irwin DE,
   2. Milsom I,
   3. Hunskaar S,
   4. Reilly K,
   5. Kopp Z,
   6. Herschorn S,
   7. et al.

   (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Stewart WF,
   2. Van Rooyen JB,
   3. Cundiff GW,
   4. Abrams P,
   5. Herzog AR,
   6. Corey R,
   7. et al.

   (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Coyne KS,
   2. Sexton CC,
   3. Irwin DE,
   4. Kopp ZS,
   5. Kelleher CJ,
   6. Milsom I

   (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101:1388–1395.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Cipullo LM,
   2. Cosimato C,
   3. Filippelli A,
   4. Conti V,
   5. Izzo V,
   6. Zullo F,
   7. et al.

   (2014) Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. Eur J Obstet Gynecol Reprod Biol 174:27–34.

   OpenUrlCrossRefPubMed
8. ↵
   1. Maman K,
   2. Aballea S,
   3. Nazir J,
   4. Desroziers K,
   5. Neine ME,
   6. Siddiqui E,
   7. et al.

   (2014) Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 65:755–765.

   OpenUrlCrossRefPubMed
9. ↵
   1. Liu B,
   2. Li P,
   3. Li J,
   4. Wang Y,
   5. Wu Y

   (2014) [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes]. Zhonghua Yi Xue Za Zhi 94:2350–2354, Chinese.

   OpenUrl
10. ↵
    1. Michel MC

    (2008) Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9:1787–1796.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Malhotra B,
    2. Gandelman K,
    3. Sachse R,
    4. Wood N,
    5. Michel MC

    (2009) The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 16:4481–4489.

    OpenUrlCrossRefPubMed
12. ↵
    1. Hoffstetter S,
    2. Leong FC

    (2009) Solifenacin succinate for the treatment of overactive bladder. Expert Opin Drug Metab Toxicol 5:345–350.

    OpenUrlPubMed
13. ↵
    1. Chapple CR,
    2. Cardozo L,
    3. Steers WD,
    4. Govier FE

    (2006) Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 60:959–966.

    OpenUrlCrossRefPubMed
14. ↵
    1. Homma Y,
    2. Yoshida M,
    3. Seki N,
    4. Yokoyama O,
    5. Kakizaki H,
    6. Gotoh M,
    7. et al.

    (2006) Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology 68:318–323.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Koike Y,
    2. Furuta A,
    3. Suzuki Y,
    4. Honda M,
    5. Naruoka T,
    6. Asano K,
    7. et al.

    (2013) Pathophysiology of urinary incontinence in murine models. Int J Urol 20:64–71.

    OpenUrl
16. ↵
    1. Yoo ES,
    2. Kim BS,
    3. Kim DY,
    4. Oh SJ,
    5. Kim JC

    (2011) The impact of overactive bladder on health-related quality of life, sexual life and psychological health in Korea. Int Neurourol J 15:143–151.

    OpenUrlCrossRefPubMed
17. ↵
    1. Cardozo L,
    2. Thorpe A,
    3. Warner J,
    4. Sidhu M

    (2010) The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 106:506–514.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Abrams P,
    2. Andersson KE,
    3. Buccafusco JJ,
    4. Chapple C,
    5. de Groat WC,
    6. Fryer AD,
    7. et al.

    (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578.

    OpenUrlCrossRefPubMed
19. ↵
    1. Lucas MG,
    2. Bosch RJ,
    3. Burkhard FC,
    4. Cruz F,
    5. Madden TB,
    6. Nambiar AK,
    7. et al.

    (2012) EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 62:1130–1142.

    OpenUrlCrossRefPubMed
20. ↵
    1. Ginsberg D,
    2. Schneider T,
    3. Kelleher C,
    4. Van Kerrebroeck P,
    5. Swift S,
    6. Creanga D,
    7. et al.

    (2013) Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int 112:373–385.

    OpenUrl
21. ↵
    1. DuBeau CE,
    2. Morrow JD,
    3. Kraus SR,
    4. Creanga D,
    5. Bavendam T

    (2012) Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn 31:1258–1265.

    OpenUrlCrossRefPubMed
22. ↵
    1. Kaplan SA,
    2. Cardozo L,
    3. Herschorn S,
    4. Grenabo L,
    5. Carlsson M,
    6. Arumi D,
    7. et al.

    (2014) Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract 68:1065–1073.

    OpenUrlPubMed
23. ↵
    1. Herschorn S,
    2. Stothers L,
    3. Carlson K,
    4. Egerdie B,
    5. Gajewski JB,
    6. Pommerville P,
    7. et al.

    (2010) Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 183:1892–1898.

    OpenUrlPubMed
24. ↵
    1. Chancellor MB,
    2. Zinner N,
    3. Whitmore K,
    4. Kobashi K,
    5. Snyder JA,
    6. Siami P,
    7. et al.

    (2008) Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 30:1766–1781.

    OpenUrlCrossRefPubMed
25. ↵
    1. Kalder M,
    2. Pantazis K,
    3. Dinas K,
    4. Albert US,
    5. Heilmaier C,
    6. Kostev K

    (2014) Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 124:794–800.

    OpenUrl
26. ↵
    1. Wagg A,
    2. Compion G,
    3. Fahey A,
    4. Siddiqui E

    (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    1. Athanasopoulos A,
    2. Giannitsas K

    (2011) An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 2011:820816.

    OpenUrlPubMed